scholarly journals Effect of Cadherin-11 Expression on the Prognosis of a Newly Diagnosed Primary Glioblastoma

2021 ◽  
Vol 9 (2) ◽  
pp. 63
Author(s):  
Hyunwoo Seo ◽  
Hye Won Lee ◽  
Sang-Youl Yoon ◽  
Sung Hyun Chang ◽  
Seong-Hyun Park ◽  
...  
Keyword(s):  
Newly Diagnosed ◽  
Primary Glioblastoma

scholarly journals Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Clemens Seidel ◽  
Nils Dörner ◽  
Matthias Osswald ◽  
Antje Wick ◽  
Michael Platten ◽  
...  
Keyword(s):  
Peritumoral Edema ◽  
Newly Diagnosed ◽  
Primary Glioblastoma ◽  
Mri Study

scholarly journals Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status

2020 ◽  
Vol 51 (1) ◽  
pp. 45-53
Author(s):  
Yusuke Tabei ◽  
Keiichi Kobayashi ◽  
Kuniaki Saito ◽  
Saki Shimizu ◽  
Kaori Suzuki ◽  
...  
Keyword(s):  
Overall Survival ◽  
Dna Methyltransferase ◽  
Median Overall Survival ◽  
Idh1 Mutation ◽  
Newly Diagnosed ◽  
Wild Type ◽  
Secondary Glioblastoma ◽  
Primary Glioblastoma ◽  
Methylguanine Dna Methyltransferase ◽  
Mutant Idh1

Abstract Backgrounds Mutations in the isocitrate dehydrogenase (IDH)1 gene are favourable prognostic factors in newly diagnosed diffuse gliomas, whereas it remains controversial in the recurrent glioblastoma setting. Methods A total of 171 patients with newly diagnosed glioblastoma, either ‘primary’ glioblastoma or ‘secondary’ glioblastoma, treated at Kyorin University Hospital or Japanese Red Cross Medical Center from 2000 to 2015 were included. Patients with confirmed IDH1 status and O6-methylguanine-DNA methyltransferase promoter methylation status were retrospectively analysed for overall survival from the initial diagnosis (n = 147) and after the first progression (n = 122). Results IDH1 mutation but not IDH2 was noted in 19 of 147 patients with glioblastoma (12.9%). In patients with ‘primary’ glioblastoma (n = 136), median overall survival after the first progression was 13.5 and 10.5 months for mutant IDH1 and wild-type IDH1 glioblastoma, respectively (P = 0.747). Multivariate analysis revealed O6-methylguanine-DNA methyltransferase promoter methylation, and Karnofsky Performance status 60 or higher, were independent prognostic factors for better overall survival after the first progression. When ‘primary’ glioblastoma and ‘secondary’ glioblastoma were combined, median overall survival from the first progression was not significantly different between the mutant IDH1 group (10.1 months) and wild-type IDH1 group (10.5 months) (P = 0.559), whereas median overall survival from the initial diagnosis was significantly different (47.5 months vs.18.3 months, respectively; P = 0.035). Conclusions These results suggest that IDH1 mutation may not be a prognostic factor for survival at the first progression of patients with ‘primary’ glioblastoma and pretreated ‘secondary’ glioblastoma, and further warrant investigation in prospective studies.

scholarly journals Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters

2014 ◽  
Vol 120 (2) ◽  
pp. 361-370 ◽  
Author(s):  
Asim K. Bag ◽  
Phillip C. Cezayirli ◽  
Jake J. Davenport ◽  
Santhosh Gaddikeri ◽  
Hassan M. Fathallah-Shaykh ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Glioblastoma Multiforme ◽  
Perfusion Imaging ◽  
Post Treatment ◽  
Newly Diagnosed ◽  
Primary Glioblastoma ◽  
Imaging Parameters

The clinical significance of fascin expression in a newly diagnosed primary glioblastoma

2016 ◽  
Vol 129 (3) ◽  
pp. 495-503 ◽  
Author(s):  
Ki-Su Park ◽  
Hye Won Lee ◽  
Seong-Hyun Park ◽  
Tae In Park ◽  
Jeong-Hyun Hwang
Keyword(s):  
Clinical Significance ◽  
Newly Diagnosed ◽  
Primary Glioblastoma

scholarly journals 332 Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A358-A358
Author(s):  
Christopher Duma ◽  
Daniela Bota ◽  
Frank Hsu ◽  
David Piccioni ◽  
Renato LaRocca ◽  
...  
Keyword(s):  
Cell Cultures ◽  
Phase Ii ◽  
Tumor Antigens ◽  
Patient Specific ◽  
Autologous Tumor ◽  
Newly Diagnosed ◽  
Tumor Initiating Cells ◽  
Eligibility Criteria ◽  
Primary Glioblastoma ◽  
Dendritic Cell Vaccines

BackgroundDespite standard aggressive therapy (maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ), then maintenance TMZ), 2-year survival is only about 25% for patients with newly diagnosed primary glioblastoma (GBM). Adding AV-GBM-1, a vaccine consisting of autologous dendritic cells (DC) pulsed with autologous tumor antigens (ATA) may improve survival. One objective of a multi-center phase II clinical trial was to determine the feasibility of collecting fresh GBM and establishing short-term cell cultures of GBM tumor-initiating cells (TIC) to serve as ATA source.MethodsKey eligibility criteria for tumor collection were (1) clinical suspicion of new primary GBM, (2) age 18 to 70 years (3) tentative agreement to undergo a leukapheresis procedure after recovery from surgery, and (4) tentative plans for RT/TMZ. Fresh tumor was placed in media and shipped in a transport kit by overnight courier to AIVITA where a cell suspension was placed in culture and incubated in serum-free medium with factors that favor survival and proliferation of TICS (stem cells and early progenitor cells). The intent was to produce a patient-specific DC-ATA vaccine by incubating a lysate of irradiated TICs with autologous DC for subsequent subcutaneous injection.ResultsPatients were enrolled from five sites in California, one in Kentucky and one in New Jersey. Tumors were collected between August 2018 and January 2020. 106 patients consented for tumor collection, but 15 were not GBM, 4 had insufficient tissue to send, 2 patients withdrew consent, 4 were ineligible because of age, and 1 was ineligible because of autoimmune disease. Of the 80 GBM tumors that were placed into culture, 7 were discontinued because of patient withdrawal. 71/73 (97%) resulted in a successful cell culture; two were unsuccessful because of contamination. 60/71 subsequently consented for intent-to-treat ; 46/60 (77%) had cells in culture for 28 days or less, 11 were in culture for 30 to 35 days, and the remaining 3 were cultured 46, 54, and 55 days. The average number of cells per culture at the time of irradiation was 14.0 million (range 0.78 to 63.3 million). 58/60 (97%) yielded more than 1 million TICs for irradiation for the tumor cell lysate; 36/60 (60%) had more than 10 million cells irradiated. 57 patients were subsequently treated with AV-GBM-1 after recovery from RT/TMZ.ConclusionsSelf-renewing GBM TIC cultures can be reliably and rapidly established for use as the antigen source for personal DC-ATA vaccines.Trial RegistrationClinicaltrialsgov NCT03400917Ethics ApprovalThis study was approved by the Western IRB, approval number 20182582; all participants gave written informed consent before taking part

scholarly journals Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO)

2012 ◽  
Vol 15 (1) ◽  
pp. 112-121 ◽  
Author(s):  
Annette Leibetseder ◽  
Michael Ackerl ◽  
Birgit Flechl ◽  
Adelheid Wöhrer ◽  
Georg Widhalm ◽  
...  
Keyword(s):  
Young Adult ◽  
Adult Patients ◽  
Adolescent And Young Adult ◽  
Molecular Characteristics ◽  
Newly Diagnosed ◽  
Primary Glioblastoma

scholarly journals Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma

2008 ◽  
Vol 10 (1) ◽  
pp. 79-87 ◽  
Author(s):  
Graziella Filippini ◽  
Chiara Falcone ◽  
Amerigo Boiardi ◽  
Giovanni Broggi ◽  
Maria G. Bruzzone ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Newly Diagnosed ◽  
Primary Glioblastoma

Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter

Cancer ◽  
2010 ◽  
Vol 117 (8) ◽  
pp. 1721-1730 ◽  
Author(s):  
Kazuya Motomura ◽  
Atsushi Natsume ◽  
Yugo Kishida ◽  
Hiroyuki Higashi ◽  
Yutaka Kondo ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Newly Diagnosed ◽  
Interferon Β ◽  
Primary Glioblastoma ◽  
Mgmt Promoter
Sign in / Sign up

Export Citation Format

Share Document